StockpollyBeta
Get App
Popularity #1,609
PVLA · NASDAQ · Biotechnology

Palvella Therapeutics (PVLA)

Develops topical QTORIN candidates for serious rare skin diseases and vascular malformations.

$148.94
vs last close−9.19 (−5.81%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue2010000000000
Cost of revenue100000000000
Gross profit1910000000000
16723548910111521
Research & development10411334577912
621122444469
General & administrative001122444469
Other expenses000000000000
Operating income3−5−2−3−5−4−8−9−10−11−15−21
−141−1−1−2000−1−1−10
Interest income100000111112
Interest expense001101112222
Other non-operating income14−1002−2−1−10030
Income before tax−11−5−3−4−7−4−8−9−11−13−16−22
Net income from continuing operations−11−5−3−4−7−4−8−9−11−13−16−22
Net income−11−5−3−4−7−4−8−9−11−13−16−22
EPS, basic−$8.70−$3.71−$2.00−$3.37−$2.19−$0.88−$3.68−$0.86−$1.03−$1.08−$1.20−$1.52
EPS, diluted−$8.70−$3.71−$2.00−$3.37−$2.19−$0.88−$3.68−$0.86−$1.03−$1.08−$1.20−$1.52
Weighted average shares, basic11111221111111314
Weighted average shares, diluted11111221111111314
EBITDA−10−5−2−3−2−3−7−80−11−18−22
Depreciation & amortization1000500010000
EBIT−11−5−2−3−7−3−7−8−10−11−18−22